DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic ...

A new randomised clinical trial – carried out by researchers at the University of Bath in the UK – found that a CGM sold by Abbott (the Freestyle Libre 2) "systemically overestimated" glucose ...

Drivers with diabetes are safer on the road if they are using a continuous glucose monitoring device that alerts them when ...

CMA CGM has taken its total spend on secondhand container ships to nearly $350m this year with the purchase of a 10th ...

Advanced Technologies & Treatments for Diabetes (ATTD) conference took place in Amsterdam, Netherlands, bringing together top ...

Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments.

Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.

DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...